![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Requests More Data From Rocket for Kresladi Gene Therapy
FDA Requests More Data From Rocket for Kresladi Gene Therapy
The FDA has issued a complete response letter to Rocket Pharmaceuticals requesting additional chemistry, manufacturing and controls information before reviewing the company’s BLA for Kresladi (marnetegragene autotemcel).
Kresladi is a lentiviral vector-based gene therapy that contains autologous (patient-derived) hematopoietic stem cells intended to treat severe leukocyte adhesion deficiency-I (LAD-I).
The company reported that top-line data from a global phase 1/2 study of Kresladi demonstrated 100 percent overall survival at 12 months post-infusion (and for the entire duration of follow up) for all nine LAD-I patients with 18 to 42 months of available follow up.
Read the complete story here.
Related Topics
Upcoming Events
-
11Jul
-
18Jul
-
21Oct